万古霉素与利奈唑胺治疗老年人院内获得性肺炎评价

目的比较利奈唑胺与万古霉素治疗G^＋菌所致老年人院内获得性肺炎的疗效和安全性。方法回顾性分析应用利奈唑胺f51例）与万古霉素f43例）治疗的老年人院内获得性肺炎患者的临床资料，比较临床有效率、细菌学清除率及不良反应情况。结果所有病原菌均对利奈唑胺和万古霉素呈现敏感。利奈唑胺和万古霉索治疗院内获得性肺炎临床有效率分别为72．5％和53．5％（P〉0．0S）。治疗耐甲氧西林金黄色葡萄球菌（MRSA）肺炎利奈唑胺组有效率76．5％，万古霉素组临床有效率50％（P〈0．05）。两组细菌清除率分别为68．6％和62．8％（P〉0．05）。利奈唑胺组与万古霉素组不良事件发生率差异无统计学意义，但老年患者耐受性利奈唑胺优于万古霉素。结论利奈唑胺治疗G^＋菌所致老年人院内获得性肺炎有较好疗效，且耐受性好。

Effect of linezolid and vancomycin on hospital-acquired pneumonia in aged patients

Objective To compare the therapeutic effect and safety of linezolid and vancomycin on hospital-acquired pneumonia caused by Gram-positive bacteria in aged patients. Methods Clinical data about 51 patients with hospital-acquired pneumonia treated with linezolid and 43 patients with hospital-acquired pneumonia treated with vancomycin were retrospectively analyzed. Therapeutic efficiency, bacterial clearance and adverse effects of linezolid and vancomycin for hospital-aquired pneumonia were compared. Results All the pathogens were sensitive to linezolid and vancomycin. The clinical efficacy of linezolid and vancomycin was 72.5% and 53_5% respectively for hospital-acquired pneumonia（P〉0.05）, and was 76.5% and 50% respectively for MRSA pneumonia（P〈0.05）, with a pathogen clearance rate of 68.6% and 62.8%, respectively（P〉0.05）. No statistical difference was found in adverse events of the two drugs. However, the tolerance of patients was better to linezolid than to vancomycin. Conclusion The therapeutic effect of linezolid is better than that of vancomycin and the tolerance of patients is also better to linezolid than to vancomycin.